Definium's DT120 ODT Achieves Significant Anxiety Improvement In Phase 3 Trial; Stock Up

Definium Therapeutics, Inc. (DFTX) announced positive topline results from Panorama, its second Phase 3 study evaluating DT120 (lysergide) Orally Disintegrating Tablet in adults with generalized anxiety disorder.